Frontiers | Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
Current issues and perspectives in PD-1 blockade cancer immunotherapy | SpringerLink
JCI - Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
IMMUNTERAPI
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment | Journal for ImmunoTherapy of Cancer
BMS-1 (PD-1/PD-L1 inhibitor 1) | PD-1/PD-L1 PPI Inhibitor | MedChemExpress
Definition of immune checkpoint inhibitor - NCI Dictionary of Cancer Terms - NCI
A PD 1 Inhibitor Fairy Tale - YouTube
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology & Oncology | Full Text
Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy - ScienceDirect
PD-1 and PD-L1 inhibitors - Wikipedia
The diverse functions of the PD1 inhibitory pathway | Nature Reviews Immunology
Frontiers | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Immune checkpoint blockade in HIV - eBioMedicine
Current Oncology | Free Full-Text | Immune Checkpoint Inhibitors in Cancer Therapy
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms - Annals of Oncology
Do Checkpoint Inhibitors Increase Rejection Risk? - Division of Nephrology
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker - Wang - 2020 - Cancer Medicine - Wiley Online Library
Opdualag Approved to Treat Advanced Melanoma - NCI
Mechanism of action of PD-1 and PD-L1 inhibitors. Tumor cells develop... | Download Scientific Diagram
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation | Journal of Medicinal Chemistry
In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | Journal for ImmunoTherapy of Cancer | Full Text
Using combination therapy to overcome insufficient responses in programmed death ligand-1 (PD-1) inhibitors
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway | Acta Pharmacologica Sinica